SCHEMBL27658355

SCHEMBL27658355

CC(=O)OCc1cc(Br)cnc1[N+](=O)[O-]

nearest known ligand 0.37

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.37
ALDH1A1 P00352 1/20 0.37
RECQL P46063 1/20 0.36
MAPT P10636 5/20 0.35
NPC1 O15118 2/20 0.35
RAB9A P51151 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
POLB P06746 1/20 0.34
HTT P42858 1/20 0.34
LMNA P02545 1/20 0.34
S1PR4 O95977 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
GLA P06280 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL990747 0.78 MAPT (0.45) KMT2AALDH1A1MAPTNPC1RAB9A
SCHEMBL22117014 0.76 TSHR (0.36) ALDH1A1MAPTSMN1; SMN2POLBHTT
SCHEMBL27678434 0.75 MET (0.43) ALDH1A1MAPTPOLBLMNA
SCHEMBL18498886 0.74 MAOB (0.40) KMT2AALDH1A1RECQLMAPTSMN1; SMN2
SCHEMBL12985694 0.73 CYP3A4 (0.35) KMT2AALDH1A1HTTHPGD
SCHEMBL27732126 0.71 KDM4E (0.40) KMT2AALDH1A1RECQLMAPTRAB9A
SCHEMBL22468486 0.70 MAPT (0.40) KMT2AALDH1A1RECQLMAPTNPC1
SCHEMBL20607733 0.69 MAPT (0.39) KMT2AALDH1A1MAPTSMN1; SMN2POLB
SCHEMBL21591695 0.69 MEN1 (0.37) KMT2ASMN1; SMN2POLB
SCHEMBL5344518 0.69 ALDH1A1 (0.44) KMT2AALDH1A1RECQLMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101933926-A Indolylmaleimde derivatives as PKC inhibitors NOVARTIS AG 2011-01-05 CN disclosed
CN-1910173-B Indolylmaleimide derivatives as PKC inhibitors NOVARTIS AG 2010-06-09 CN disclosed
CN-1910173-A Indolylmaleimide derivatives as PKC inhibitors NOVARTIS AG (CH) 2007-02-07 CN disclosed